Zhong Guo Ji Jin Bao·2026-01-13 10:45Core Viewpoint - The pharmaceutical sector, particularly companies integrating AI technologies, has shown significant growth, with Ark Health experiencing a surge of over 76% in stock price, while WuXi AppTec and WuXi Biologics led the blue-chip stocks with notable gains [2][8]. Group 1: Market Performance - The Hang Seng Index rose by 0.9% to close at 26,848.47 points, with a total market turnover of HKD 315.19 billion, an increase from HKD 306.22 billion in the previous trading day [2]. - Among the constituents of the Hang Seng Index, 53 stocks increased while 33 declined, with WuXi AppTec rising by 8.30% and WuXi Biologics by 5.85% [4]. - Notable stock performances included Alibaba, which increased by 3.63%, and China Life, which rose by 3.51% [4]. Group 2: Company Highlights - Ark Health's stock opened with a peak increase of 76.37%, closing at HKD 3.93 per share, marking a daily increase of 65.8% due to its collaboration with Tencent Health in the "AI + Chronic Disease Management" sector [8][9]. - WuXi AppTec's stock price surged by 9.66% to close at HKD 120 per share, driven by a positive earnings forecast indicating a projected net profit growth of approximately 102.65% for 2025 [10][12]. - WuXi Biologics also saw a significant increase, with a maximum rise of 6.92%, closing at HKD 39.78 per share, as the company prepares to present at the 44th Annual J.P. Morgan Healthcare Conference [16][17]. Group 3: Financial Projections - WuXi AppTec's earnings forecast includes an expected revenue of approximately HKD 45.46 billion for 2025, reflecting a year-on-year growth of about 15.84%, with adjusted net profit projected at HKD 14.96 billion, a 41.33% increase [12][13]. - WuXi Biologics anticipates signing a record 209 new projects in 2025, with a focus on expanding its commercial pipeline and maintaining a positive outlook for revenue growth in 2026 [20].